Your browser doesn't support javascript.
loading
IL-4Rα Inhibitor for Atopic Disease.
Chang, Howard Y; Nadeau, Kari C.
Affiliation
  • Chang HY; Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: howchang@stanford.edu.
  • Nadeau KC; Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: knadeau@stanford.edu.
Cell ; 170(2): 222, 2017 Jul 13.
Article in En | MEDLINE | ID: mdl-28708993
ABSTRACT
Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Dermatitis, Atopic / Antibodies, Monoclonal Limits: Humans Language: En Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Dermatitis, Atopic / Antibodies, Monoclonal Limits: Humans Language: En Year: 2017 Type: Article